Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines has a promising outlook, driven by anticipated growth in partnership revenues from the upcoming launches of zanidatamab and tarlatamab in China, alongside steady contributions from established products like Xgeva and Kyprolis. The company's leading product, Brukinsa, is expected to see approximately $936 million in sales for the second quarter of 2024, bolstered by increased prescription volumes and market recovery in Europe. Additionally, the potential for new drug approaches and a projected ~$650 million increase in sales from lymphoma indications by 2034 further solidify an optimistic financial trajectory for BeOne.

Bears say

BeOne Medicines faces a challenging financial outlook primarily due to the slower-than-expected uptake of its commercial products, particularly Brukinsa, which constitutes over 60% of its revenue. The company is at risk of significant downside if it fails to successfully expand its drug indications and pipeline programs, as evidenced by its setbacks in the solid tumor initiative and other drug candidates. Additionally, perceived geopolitical risks associated with being a Chinese biotechnology firm and ongoing concerns regarding cash burn further complicate its financial stability, especially within a competitive hematology-oncology market.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $374.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $374.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.